FLT3 and myeloproliferative neoplasm: Furthermore, only a small proportion of MDS/MPN patients could benefit from targeted therapeutic options, since gene mutations involving genes that are targetable (e.g., IDH1/2, FLT3, TP53) only affect a small subset of patients (<5%).